A secret that hides Novo Nordisk ADR’s strength (NYSE:NVO)

Stocks of Novo Nordisk ADR (NYSE:NVO) traded higher last session on Wall Street, up 0.07% to $101.76.

According to the data, Novo Nordisk ADR (NYSE:NVO) has 28 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $126.05 and a low of $50.84, we find $110.77. Given the previous closing price of $101.69, this indicates a potential upside of 8.93 percent. NVO stock price is now 6.51% away from the 50-day moving average and 22.19% away from the 200-day moving average. The market capitalization of the company currently stands at $343.43B.

A total of 7 analysts have issued a hold rating and 16 have given it a buy rating. Brokers who have rated the stock have averaged $103.18 as their price target over the next twelve months.

With the price target of $110, Argus recently initiated with Buy rating for Novo Nordisk ADR (NYSE: NVO).

A total of 0.00% of the company’s stock is owned by insiders.

Wednesday’s opening bell rang with an opening price of $101.98 for Novo Nordisk ADR (NYSE: NVO). During the past 12 months, Novo Nordisk ADR has had a low of $54.85 and a high of $104.00. As of last week, the company has a debt-to-equity ratio of 0.29, a current ratio of 0.82, and a quick ratio of 0.65. According to the stock market information, the enterprise value for the company is $447.55B, which is based on a 42.29 price-to-earnings ratio, a 15.10 price-to-earnings-growth ratio, and a beta of 0.40. The fifty day moving average price for NVO is $95.54 and a two-hundred day moving average price translates $83.28 for the stock.

The latest earnings results from Novo Nordisk ADR (NYSE: NVO) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at $0.61, missing analysts’ expectations of $0.63 by -0.02. This compares to $0.43 EPS in the same period last year. The net profit margin was 35.20% and return on equity was 93.02% for NVO. The company reported revenue of $8.57 billion for the quarter, compared to $6.17 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 39.09 percent. For the current quarter, analysts expect NVO to generate $7.91B in revenue.

Novo Nordisk ADR(NVO) Company Profile

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Related Posts